Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients
Authors:
Open Access
- 23 December 2020
- journal article
- research article
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 58 (6) , 350-356
Abstract
Introduction: Rheumatoid arthritis (RA) is categorized as an autoimmune disease with a frequency of 0.2–1% worldwide. It is reported that various autoantibodies are produced in the RA population, particularly against citrullinated peptides. Among various candidate markers for RA diagnosis, the citrullinated proteins have the highest specificity and sensitivity for both diagnosis and prognosis of RA. Anti-mutated citrullinated vimentin and -enolase constitute a new class of autoantibodies for early detection of RA.Material and methods: 45 serum samples and 19 synovial fluid (SF) specimens collected from RA patients were considered for American College of Rheumatology criteria and 20 serum samples and 10 SF specimens were provided from healthy subjects as a control group. To assess the quantity of anti-citrullinated protein antibodies (ACPA), anti-mutated citrullinated vimentin (MCV) and anti--enolase in the serum and SF of RA patients were determined by the enzyme-linked immunosorbent assay (ELISA) method. For the evaluation of disease activity and joint destruction, we used the Disease Activity Score of 28 joints based on erythrocyte sedimentation rate (ESR) Disease Activity Score 28 (DAS28). Furthermore, to measure the molecular weight of vimentin and -enolase, electrophoresis on 10% SDS-PAGE was performed as described before.Results: The anti--enolase level among serum samples from RA patients was significantly higher than in healthy subjects (4.49 ±0.20 ng/ml vs. 0.76 ±0.12 ng/ml) (p < 0.001). There was a direct relation between -enolase quantity and (rheumatoid factor) RF and C-reactive protein (CRP) levels. The mean ESR value in positive and negative ACPA patients was 38.2 ±22.6 mm/h and 9.2 ±5.8 mm/h respectively (p < 0.0001). The mean DAS28-ESR was 3.3. The level of anti-MCV in the serum of RA patients (244.6 ±53.3 U/ml) was higher than in serum of the healthy group (148.73 ±71.8) (p < 0.0001). The level of anti-MCV in the SF of patients was 687.5 ±148.4 U/ml.Conclusions: In conclusion, both autoantibodies against MCV and -enolase are two important markers that increase in serum and SF of RA patients and are specific for diagnosis of RA disease.Keywords
This publication has 34 references indexed in Scilit:
- Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritisRheumatology, 2011
- Specific interaction between genotype, smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid arthritisNature Genetics, 2009
- The Anti-mutated Citrullinated Vimentin Response Classifies Patients with Rheumatoid Arthritis into Broad and Narrow RespondersThe Journal of Rheumatology, 2009
- Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 allelesAnnals of the Rheumatic Diseases, 2009
- Rheumatoid arthritisThe Lancet, 2009
- Antibodies to citrullinated α‐enolase peptide 1 are specific for rheumatoid arthritis and cross‐react with bacterial enolaseArthritis & Rheumatism, 2008
- Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort studyArthritis Research & Therapy, 2008
- Molecular architecture of intermediate filamentsBioEssays, 2003